AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
- DOI
- 10.1136/jitc-2026-015474
- Published
- 2026 Sep 24
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2026-015474,
title = {AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.},
author = {Lu S and Yu Y and Zhang J and Wang Q and Cho EK and Zhao J and Kim SH and Lee Y and Clay TD and Yang TY and Chang GC and Yang H and Zuo Y and Liu R and Sun P and Kim HR},
year = {2026},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2026-015474},
url = {https://doi.org/10.1136/jitc-2026-015474}
}RIS
TY - JOUR TI - AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer. AU - Lu S AU - Yu Y AU - Zhang J AU - Wang Q AU - Cho EK AU - Zhao J AU - Kim SH AU - Lee Y AU - Clay TD AU - Yang TY AU - Chang GC AU - Yang H AU - Zuo Y AU - Liu R AU - Sun P AU - Kim HR PY - 2026 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2026-015474 UR - https://doi.org/10.1136/jitc-2026-015474 ER -
APA
S, L., Y, Y., J, Z., Q, W., EK, C., J, Z., SH, K., Y, L., TD, C., TY, Y., GC, C., H, Y., Y, Z., R, L., P, S., & HR, K. (2026). AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-015474